CoChat

The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease

Sands, Bruce E. · 2009 · Digestive Diseases

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

The placebo response is the efficacy attributable to a treatment that is thought to have no specific pharmacologic effect on the condition being treated. Although potentially helpful in clinical practice, high and unpredictable placebo response rates present a major impediment to the success of clinical trials in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Diverse factors contribute to the placebo response rates observed in clinical trials. These include patient characteristics, physician factors, frequency of study visits, characteristics of the outcome measures, concomitant treatments, regression to the mean, properties of the intervention and treatment setting, timing of the primary endpoint and natural history of the condition. Measures that may minimize the placebo response in IBD clinical trials include early timing of the primary endpoint, minimizing the number of study visits, restricting the patient population to those with documented inflammation (such as elevated biomarkers of inflammation or evidence of mucosal inflammation), including patients with more severe symptoms (i.e. greater disease activity) and enrolling patients with prior failure of immune modulators or biologics. Attempts to limit the placebo response in IBS studies have proven more difficult. Factors associated with higher placebo response rates in IBS studies include longer duration of treatment, greater number of office visits, frequency of administration of study intervention and overall treatment effect of the active agent under study. In the future, improved understanding of the factors that drive the placebo response rate should lead to more efficient study design and drug development.

Overview

Integrity signals

Registry

Crossref · 10.1159/000268123

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. 10.1001%2fjama.273.5.408 · doi:10.1001/jama.273.5.408

Cited by

See all 19

Metadata

Authors
Sands, B. E.
Affiliations
Harvard University (US)
Corresponding author
Sands, Bruce E.
Venue
Digestive Diseases
Publisher
S. Karger AG
Published
2009
Volume
27
Issue
Suppl. 1
Pages
68-75
ISSN
  • 0257-2753 (ISSN-L)
  • 1421-9875
OpenAlex
W1990410520
Cited by
17
References
23
Citations by year
2022: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 4
FWCI
0.97
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Digestive Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
placebo response, irritable bowel syndrome, inflammatory bowel disease, clinical trial design, regression to the mean, biomarkers of inflammation, mucosal inflammation, immunomodulators, biologics, treatment duration
MeSH terms
Colitis, Ulcerative, Crohn Disease, Humans, Placebos, Inflammatory Bowel Diseases, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.